- Home
- ATXS vs CTMX Comparison
ATXS vs CTMX Comparison
Compare ATXS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- CTMX
- Stock Information
- Founded
- ATXS 2008
- CTMX 2008
- Country
- ATXS United States
- CTMX United States
- Employees
- ATXS N/A
- CTMX N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- CTMX Health Care
- Exchange
- ATXS Nasdaq
- CTMX Nasdaq
- Market Cap
- ATXS 401.2M
- CTMX 444.3M
- IPO Year
- ATXS 2015
- CTMX 2015
- Fundamental
- Price
- ATXS $6.65
- CTMX $2.40
- Analyst Decision
- ATXS Strong Buy
- CTMX Strong Buy
- Analyst Count
- ATXS 7
- CTMX 2
- Target Price
- ATXS $32.43
- CTMX $5.00
- AVG Volume (30 Days)
- ATXS 304.1K
- CTMX 1.5M
- Earning Date
- ATXS 08-11-2025
- CTMX 08-07-2025
- Dividend Yield
- ATXS N/A
- CTMX N/A
- EPS Growth
- ATXS N/A
- CTMX 128.27
- EPS
- ATXS N/A
- CTMX 0.49
- Revenue
- ATXS N/A
- CTMX $147,557,000.00
- Revenue This Year
- ATXS N/A
- CTMX N/A
- Revenue Next Year
- ATXS N/A
- CTMX N/A
- P/E Ratio
- ATXS N/A
- CTMX $4.97
- Revenue Growth
- ATXS N/A
- CTMX 23.81
- 52 Week Low
- ATXS $3.56
- CTMX $0.40
- 52 Week High
- ATXS $12.92
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- ATXS 60.88
- CTMX 51.91
- Support Level
- ATXS $5.94
- CTMX $2.32
- Resistance Level
- ATXS $6.49
- CTMX $2.47
- Average True Range (ATR)
- ATXS 0.34
- CTMX 0.14
- MACD
- ATXS -0.00
- CTMX -0.01
- Stochastic Oscillator
- ATXS 74.74
- CTMX 17.89
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.